The German oncolytic virus therapy market is estimated to grow at a CAGR of more than 14% during the forecast period. Germany is considered as one of the major economies for the global oncolytic virus therapy market. This is largely due to the increasing geriatric population owing to which the risk associated with numerous types of cancers is expected to increase significantly in the near future. Moreover, the presence of highly specialized urologists for cancer treatment and a more feasible cost compared to UK attracting medical tourism in the country, which is also expected to create opportunities for the growth of the market in the near future.

Request a Free Report on Sample of Germany Oncolytic Virus Therapy Market @ https://www.omrglobal.com/request-sample/germany-oncolytic-virus-therapy-market

Further, the German oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share of over 94% in 2018, whereas, adenoviruses-based therapy held the rest. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.

A full Report of Germany Oncolytic Virus Therapy Market at https://www.omrglobal.com/industry-reports/germany-oncolytic-virus-therapy-market

The report covers the analysis of several players such as Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Medigene AG, Orca Therapeutics, OncoTheis, and others operating in the German oncolytic virus therapy market. In March 2018, Medigene AG started phase I/II clinical trial CD-TCR-001 (NCT03503968) with TCR-T cell immunotherapy MDG1011 for the treatment of various types of blood cancer. The MDG1011 is a company’s first clinical TCR-T immunotherapy product candidate, with its first clinical trial with a TCR-T therapy in Germany. The phase I/II trial investigates the safety of MDG1011 to treat various types of blood cancer, which include acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM).

Germany Oncolytic Virus Therapy Market Segmentation

By Product

• HSV-Based Oncolytic Virus
• Adenoviruses-Based Oncolytic Virus
• Vaccinia Virus-Based Oncolytic Virus
• Vesicular Stomatitis Virus-Based Oncolytic Virus
• Newcastle Disease Virus- Based Oncolytic Virus
• Others

By Application

• Prostate Cancer
• Breast Cancer
• Ovarian Cancer
• Melanoma
• Others

Company Profiles

• AbbVie, Inc.
• Amgen, Inc.
• Bristol-Myers Squibb Company
• Cold Genesys Inc.
• Creative Biolabs Inc.
• Cynvec LLC
• DNAtrix Inc.
• Genelux Corp.
• Janssen Biotech Inc.
• Merck & Co., Inc.
• Oncolytic Biotech, Inc.
• Oncorus Inc.
• Sorrento Therapeutics Inc.
• Vyriad

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/germany-oncolytic-virus-therapy-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404
Visit for https://www.omrglobal.com/industry-reports/oncolytic-virus-therapy-market